Virginia Steen

Active 1975–2025

140
Papers
33,781
Citations
94
h-index
140
i10-index

Citations

Citations per year for Virginia Steen1960: 1 citations1975: 1 citations1976: 1 citations1977: 2 citations1978: 1 citations1979: 1 citations1982: 2 citations1983: 2 citations1984: 5 citations1985: 14 citations1986: 15 citations1987: 14 citations1988: 29 citations1989: 20 citations1990: 33 citations1991: 14 citations1992: 29 citations1993: 16 citations1994: 31 citations1995: 13 citations1996: 50 citations1997: 37 citations1998: 59 citations1999: 48 citations2000: 85 citations2001: 105 citations2002: 112 citations2003: 203 citations2004: 179 citations2005: 170 citations2006: 219 citations2007: 280 citations2008: 231 citations2009: 256 citations2010: 248 citations2011: 189 citations2012: 188 citations2013: 161 citations2014: 185 citations2015: 153 citations2016: 200 citations2017: 193 citations2018: 154 citations2019: 857 citations2020: 891 citations2021: 889 citations2022: 727 citations2023: 428 citations2024: 754 citations2025: 328 citations2026: 8 citations1961–1974: no citations, so these years are not shown1980–1981: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,239 citing papers, 25% of this breakdownUnited Kingdom: 763 citing papers, 8.5% of this breakdownItaly: 722 citing papers, 8.1% of this breakdownFrance: 586 citing papers, 6.5% of this breakdownGermany: 470 citing papers, 5.2% of this breakdownCanada: 413 citing papers, 4.6% of this breakdownChina: 330 citing papers, 3.7% of this breakdownJapan: 315 citing papers, 3.5% of this breakdownSwitzerland: 311 citing papers, 3.5% of this breakdownNetherlands: 289 citing papers, 3.2% of this breakdownSpain: 225 citing papers, 2.5% of this breakdownAustralia: 219 citing papers, 2.4% of this breakdown
0%25%Other 23.3%

Fields

  • Medicine92.2%
  • Biochemistry, Genetics and Molecular Biology3.3%
  • Immunology and Microbiology1.8%
  • Engineering0.5%
  • Health Professions0.4%
  • Psychology0.3%
  • Other1.5%

Topics

  • Systemic Sclerosis and Related Diseases18%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis8.3%
  • Inflammatory Myopathies and Dermatomyositis6.9%
  • Pulmonary Hypertension Research and Treatments4.6%
  • Systemic Lupus Erythematosus Research3.6%
  • Rheumatoid Arthritis Research and Therapies2.7%
  • Other55.9%

Coauthors

All papers

Open in search
  1. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David H. Collier, Mary Ellen Csuka, Barri J. Fessler, Serena Guiducci, Ariane L. Herrick, Vivien Hsu, Sergio A. Jiménez, Bashar Kahaleh, Peter A. Merkel, S. Sierakowski, Richard M. Silver, Robert W. Simms, John Varga, Janet Pope - Annals of the Rheumatic Diseases 2013 cited by 3,406

  2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mette Mogensen, Anne Braae Olesen, Yannick Allanore, J. Henes, Ulf Müller‐Ladner, Gabriela Riemekasten, Alla Skapenko, Panayiotis G. Vlachoyiannopoulos, Emese Kiss, Tünde Minier, Lorenzo Beretta, Elisa Gremese, Marco Matucci‐Cerinic, Gabriele Valentini, Yoshihide Asano, Tatsuya Atsumi, Hironobu Ihn, Tomonori Ishii, Osamu Ishikawa, Masataka Kuwana, Yoshihito Shima, Hiroki Takahashi, Kazuhiko Takehara, Yoshiya Tanaka, Yoshioki Yamasaki, Loreta Bukauskienė, İrena Butrimienė, Gabriel Medrano Ramírez, César Ramos-Remus, Tatiana Sofía Rodríguez Reyna, Jeska de Vries‐Bouwstra, Jacob M. van Laar, Bogdan Batko, Sławomir Jeka, Eugeniusz J. Kucharz, Maria Majdan, Marzena Olesińska, Żaneta Smoleńska, José Delgado Alves, María José Santos, C. Mihai, Simona Rednic, Ivan Castellvi Barranco, Francisco Longo, C Simeόn Aznar, Patrícia Carreira, Oliver Distler, Ulrich A. Walker, Emma Derrett‐Smith, Bridget Griffiths, Neil D McKay, Christopher P. Denton, Jacob Aelion, Michael Borofsky, Roy Fleischmann, Joseph Z. Forstot, Daniel E. Furst, Suzanne Kafaja, Mahmuda Khan, Dinesh Khanna, Michael Kohen, Richard W. Martin, Fabian Mendoza-Ballesteros, Alireza Nami, Shirley Pang, Grissel Ríos, Robert W. Simms, Keith M. Sullivan, Virginia Steen - The Lancet Respiratory Medicine 2020 cited by 652

  3. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nancy Sullivan, Laura Tarter, Mehret Birru Talabi, Marat Turgunbaev, Amy S. Turner, Kristen E. D’Anci - Arthritis & Rheumatology 2020 cited by 749

  4. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard T. Meehan, Arthur C. Theodore, Robert W. Simms, Suncica Volkov, Dean E. Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A. Molitor, Kristin B. Highland, Charles A. Read, Marvin J. Fritzler, Grace Hyun J. Kim, Chi‐Hong Tseng, Robert M. Elashoff - The Lancet Respiratory Medicine 2016 cited by 1,062

  5. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 cited by 669

  6. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark L. Metersky - New England Journal of Medicine 2006 cited by 1,667

  7. Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2023 cited by 160

  8. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , - Journal of Scleroderma and Related Disorders 2017 cited by 521

  9. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2019 cited by 178

  10. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Respiratory Research 2023 cited by 142

  11. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

    Authors: , , , , , , , , , , , , , - Arthritis & Rheumatism 1998 cited by 2,673

  12. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

    Authors: , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2018 cited by 198

  13. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yue Wang, Tammara Wood, Yannick Allanore, M. Matucci-Cerinic, Oliver Distler, Ora Singer, Erica Bush, David A. Fox, Daniel E. Furst - Arthritis & Rheumatology 2019 cited by 224

  14. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 cited by 107

  15. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis

    Authors: , , , , , , , , , , , , - Arthritis & Rheumatology 2020 cited by 74

  16. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher P. Denton, the RESOLVE‐1 Study Group - Arthritis & Rheumatology 2023 cited by 43

  17. Therapy for Pulmonary Arterial Hypertension in Adults

    Authors: , , , , , , , , , , , , - CHEST Journal 2019 cited by 299

  18. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2016 cited by 156

  19. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

    Authors: , , , , , , , , , , , , , , , , , , , - Arthritis Research & Therapy 2021 cited by 69

  20. Severe organ involvement in systemic sclerosis with diffuse scleroderma

    Authors: , - Arthritis & Rheumatism 2000 cited by 923

  21. Autoantibodies in Systemic Sclerosis

    Authors: - Seminars in Arthritis and Rheumatism 2005 cited by 679

  22. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2017 cited by 258

  23. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis

    Authors: , , , , - Arthritis & Rheumatism 2012 cited by 171

  24. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark L. Metersky, Dinesh Khanna, Ning Li, Gang Li - American Journal of Respiratory and Critical Care Medicine 2007 cited by 464